A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer

Phase 2 Withdrawn Pfizer Medivation, Inc. · collab Myriad Genetic Laboratories, Inc. · collab

RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this phase 2, multiple-cohort, randomized, open-label, international study of talazoparib (a poly (ADP-ribose) polymerase (PARP) inhibitor) is to compare the efficacy and safety of talazoparib monotherapy and talazoparib plus temozolomide in women with relapsed ovarian, fallopian tube, and peritoneal cancer.

Timeline

Start: 2016-10
Primary completion: 2020-06
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Talazoparib	Small molecule	1 mg	Oral
Comparator	Temozolomide	Small molecule	37.5 mg/m2	—

A Study Evaluating Talazoparib in Relapsed Ovarian, Fallopian Tube, and Peritoneal Cancer

Summary

Timeline

Drugs

Indications